Carlos Martín-Saborido1, Jesús López-Alcalde2,3,4, Agustín Ciapponi5, Carlos Enrique Sánchez Martín6, Elena Garcia Garcia7, Gema Escobar Aguilar8, Maria Carolina Palermo9, Fernando G Baccaro10. 1. San Juan De Dios Foundation, Health Sciences University Centre, Antonio de Nebrija University, Research on Evidence and Decision Making Group, Paseo de la Habana 70 bis, Madrid, Comunidad de Madrid, Spain, 28036. 2. Cochrane Associate Centre of Madrid, Ctra. Colmenar Km. 9,100, Madrid, Madrid, Spain, 28034. 3. Universidad Francisco de Vitoria, Faculty of Medicine, Ctra. M-515 Pozuelo-Majadahonda, Pozuelo de Alarcón, Madrid, Spain, 28223. 4. Instituto Ramón y Cajal de Investigación Sanitaria, Clinical Biostatistics Unit, Ctra. Colmenar, km. 9.100, Madrid, Spain, 28034. 5. Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Argentine Cochrane Centre, Dr. Emilio Ravignani 2024, Buenos Aires, Capital Federal, Argentina, C1414CPV. 6. San Carlos Clinical Hospital, Department of Anesthesiology, Madrid, Madrid, Spain. 7. San Juan De Dios Foundation, Health Services Research Department, C/Herreros de Tejada, Madrid, Spain, 3-28016. 8. San Juan de Dios Foundation/San Rafael-Nebrija Health Sciences Center, Nebrija University, Health Services Research Unit, Herreros de Tejada, 5, Madrid, Spain, 28036. 9. University of Buenos Aires, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina. 10. Juan A Fernández Hospital, Intensive Care Unit, Cerviño 3356, Buenos Aires, Argentina, 1425.
Abstract
BACKGROUND: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. OBJECTIVES: To assess the effects of indomethacin for adults with severe traumatic brain injury. SEARCH METHODS: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. SELECTION CRITERIA: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. DATA COLLECTION AND ANALYSIS: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. MAIN RESULTS: We identified no eligible studies for this review, either completed or ongoing. AUTHORS' CONCLUSIONS: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
BACKGROUND: Among people who have suffered a traumatic brain injury, increased intracranial pressure continues to be a major cause of early death; it is estimated that about 11 people per 100 with traumatic brain injury die. Indomethacin (also known as indometacin) is a powerful cerebral vasoconstrictor that can reduce intracranial pressure and, ultimately, restore cerebral perfusion and oxygenation. Thus, indomethacin may improve the recovery of a person with traumatic brain injury. OBJECTIVES: To assess the effects of indomethacin for adults with severe traumatic brain injury. SEARCH METHODS: We ran the searches from inception to 23 August 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8) in the Cochrane Library, Ovid MEDLINE, Ovid Embase, CINAHL Plus (EBSCO), four other databases, and clinical trials registries. We also screened reference lists and conference abstracts, and contacted experts in the field. SELECTION CRITERIA: Our search criteria included randomised controlled trials (RCTs) that compared indomethacin with any control in adults presenting with severe traumatic brain injury associated with elevated intracranial pressure, with no previous decompressive surgery. DATA COLLECTION AND ANALYSIS: Two review authors independently decided on the selection of the studies. We followed standard Cochrane methods. MAIN RESULTS: We identified no eligible studies for this review, either completed or ongoing. AUTHORS' CONCLUSIONS: We found no studies, either completed or ongoing, that assessed the effects of indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. Thus, we cannot draw any conclusions about the effects of indomethacin on intracranial pressure, mortality rates, quality of life, disability or adverse effects. This absence of evidence should not be interpreted as evidence of no effect for indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury. It means that we have not identified eligible research for this review.
Authors: Jui-Lin Fan; Keith R Burgess; Kate N Thomas; Karen C Peebles; Samuel J E Lucas; Rebekah A I Lucas; James D Cotter; Philip N Ainslie Journal: Eur J Appl Physiol Date: 2010-10-12 Impact factor: 3.078
Authors: Carlos Martín-Saborido; Jesús López-Alcalde; Agustín Ciapponi; Carlos Enrique Sánchez Martín; Elena Garcia Garcia; Gema Escobar Aguilar; Maria Carolina Palermo; Fernando G Baccaro Journal: Cochrane Database Syst Rev Date: 2019-11-22